Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.64 |
| ▸ | ACACA | Q13085 | 2/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23578433 | 0.95 | ACACB (0.57) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL23588315 | 0.89 | TP53 (0.50) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL30880252 | 0.85 | ACACB (0.56) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL23588220 | 0.84 | FFAR1 (0.46) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL23578296 | 0.83 | S1PR1 (0.49) | ACACBACACATP53S1PR1FFAR1 | |
| SCHEMBL23578031 | 0.83 | FFAR1 (0.56) | FFAR1GSTP1TDP1L3MBTL1NPC1 | |
| SCHEMBL27291369 | 0.82 | MITF (0.43) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL23578166 | 0.82 | ACACB (0.48) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL25291455 | 0.82 | ACACB (0.48) | ACACBACACAMITFTP53NCOA3 | |
| SCHEMBL23578165 | 0.82 | ACACB (0.48) | ACACBACACAMITFTP53NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | claimed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | claimed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | claimed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | claimed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | claimed |
| EP-4081511-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2022-11-02 | — | — | EP | claimed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | claimed |
| WO-2021130492-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2021-07-01 | — | — | WO | claimed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4442319-A2 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4081511-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2022-11-02 | — | — | EP | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021130492-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130492-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | ACACB 358/4885ACACA 144/4885MITF 4809/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ACACB 985/4885ACACA 450/4885MITF 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.